|
Tetralogy of Fallot
|
0.200 |
Biomarker
|
disease |
MGD |
|
|
|
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Bone morphogenetic protein-10 (BMP-10) may function as a tumor suppressor in breast cancer.
|
20608934 |
2010 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Bone morphogenetic protein-10 (BMP10), a novel member of the bone morphogenetic protein (BMP) family, has been indicated as a possible tumour suppressor in prostate and breast cancer.
|
23645739 |
2013 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Bone morphogenetic protein-10 (BMP10), a novel member of the bone morphogenetic protein (BMP) family, has been indicated as a possible tumour suppressor in prostate and breast cancer.
|
23645739 |
2013 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
BMP-10 overexpression or knockdown significantly inhibited or promoted proliferation, migration, and invasion of ovarian cancer cells, respectively.
|
30401582 |
2019 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
BMP10 suppresses hepatocellular carcinoma progression via PTPRS-STAT3 axis.
|
31417183 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Altogether, our data show that in a tumor environment BMP9 and BMP10 play different roles and thus blocking their shared receptor ALK1 is maybe not appropriate.
|
30165893 |
2018 |
|
Hirschsprung Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
BMP2, BMP5 and BMP10 are elevated in the stenotic colon segment of HSCR, and BMPs signaling plays a pivotal role in the development of HSCR.
|
24551273 |
2014 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
BMP9, but not BMP10, acts as a quiescence factor on tumor growth, vessel normalization and metastasis in a mouse model of breast cancer.
|
30165893 |
2018 |
|
Pulmonary arterial hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
Characterization of <i>GDF2</i> Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension.
|
31661308 |
2020 |
|
Hirschsprung Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Dysregulation of BMP10 has been observed in several diseases, including hypertensive cardiac hypertrophy, Hirschsprung disease and blood vessel formation.
|
31417183 |
2019 |
|
Carcinoma breast stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
For this, we used knockout (KO) mice for BMP9 (constitutive Gdf2-deficient), for BMP10 (inducible Bmp10-deficient) and double KO mice (Gdf2 and Bmp10) in a syngeneic immunocompetent orthotopic mouse model of spontaneous metastatic breast cancer (E0771).
|
30165893 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical staining and quantitative real-time PCR revealed a decreased expression of BMP-10 in breast cancer.
|
20608934 |
2010 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical staining and quantitative real-time PCR revealed a decreased expression of BMP-10 in breast cancer.
|
20608934 |
2010 |
|
Ventricular hypertrophy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In adults, BMP10 expression is restricted to the right atrium, though ventricular hypertrophy is accompanied by increased BMP10 expression in a rat hypertension model.
|
26631724 |
2016 |
|
Hypertensive disease
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In adults, BMP10 expression is restricted to the right atrium, though ventricular hypertrophy is accompanied by increased BMP10 expression in a rat hypertension model.
|
26631724 |
2016 |
|
Hypertensive disease
|
0.030 |
Biomarker
|
group |
BEFREE |
In agreement with these observations, we found that the BMP9/BMP10 ligand trap ALK1<sub>ECD</sub> administered in monocrotaline or Sugen/hypoxia (SuHx) rats substantially attenuate proliferation of pulmonary vascular cells, inflammatory cell infiltration, and regresses established pulmonary hypertension in rats.
|
30636542 |
2019 |
|
Left Ventricular Hypertrophy
|
0.200 |
Biomarker
|
disease |
RGD |
Interaction of BMP10 with Tcap may modulate the course of hypertensive cardiac hypertrophy.
|
17921333 |
2007 |
|
ovarian neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Kaplan-Meier analysis revealed that low BMP-10 expression was significantly associated with poor prognosis of patients with ovarian cancer.
|
30401582 |
2019 |
|
Malignant neoplasm of ovary
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Kaplan-Meier analysis revealed that low BMP-10 expression was significantly associated with poor prognosis of patients with ovarian cancer.
|
30401582 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Kaplan-Meier analysis revealed that low BMP-10 expression was significantly associated with poor prognosis of patients with ovarian cancer.
|
30401582 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Mechanism study revealed that BMP10 suppressed tumor cell growth by inhibiting STAT3 signaling.
|
31417183 |
2019 |
|
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, the intraperitoneal administration of recombinant human BMP10 (rhBMP10) was found to effectively protect hearts from injury, suggesting potential therapeutic utility of using BMP10 to prevent heart failure.
|
31712309 |
2019 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, the intraperitoneal administration of recombinant human BMP10 (rhBMP10) was found to effectively protect hearts from injury, suggesting potential therapeutic utility of using BMP10 to prevent heart failure.
|
31712309 |
2019 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our recent study showed that a novel member of bone morphogenetic protein (BMP) family, BMP-10, was decreased in prostate cancer.
|
20608934 |
2010 |